Phase 1, Open-label, Study of Voruciclib in Subjects With Relapsed and/or Refractory B Cell Malignancies or AML After Failure of Prior Standard Therapies and Voruciclib in Combination With Venetoclax in Subjects With Relapsed/Refractory AML

This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML

开始日期2018-05-31

申办/合作机构

Lite Strategy, Inc.

NCT02117336

/ Suspended临床1期

A Phase I/Ib Study of P1446A-05 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).

This is an open-label, Phase I/Ib trial with a dose escalation phase, followed by a dose extension phase. The objective of the dose escalation phase is to evaluate the pharmacokinetics (PK) and MTD of P1446A-05 in relapsed/refractory CLL and the objective of the dose extension phase is to evaluate the safety, efficacy and pharmacodynamics of P1446A-05 in 14 patients at the MTD level.

开始日期2014-06-01

申办/合作机构

Piramal Enterprises Ltd.

[+1]

NCT01841463

/ Suspended临床1期

An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

* An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation
* The primary objective is to determine the safety, maximum tolerated dose (MTD), and dose limiting toxicity (DLT) of the co-administration of P1446A-05 with vemurafenib, in melanoma patients with BRAF mutation

开始日期2013-08-01

申办/合作机构

Piramal Enterprises Ltd.

[+1]

100 项与 Voruciclib Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Voruciclib Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Voruciclib Hydrochloride 相关的专利（医药）

登录后查看更多信息

项与 Voruciclib Hydrochloride 相关的文献（医药）

2025-08-01·Blood Neoplasia

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Article

作者: Tang, Min ; Abedin, Sameem ; Keng, Michael ; Ghalie, Richard G ; Davids, Matthew S ; Javidi-Sharifi, Nathalie ; Rajagopalan, Prabhu ; Cook, Rachel J ; Wiley, Sandra E ; Dinner, Shira N ; Begna, Kebede H ; Al Malki, Monzr M ; Alvarado-Valero, Yesid ; Bhatt, Vijaya Raj

The antiapoptotic protein myeloid cell leukemia 1 (Mcl-1) promotes cell survival in acute myeloid leukemia (AML), and its overexpression is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, indirectly decreases Mcl-1 protein expression and has synergistic activity with venetoclax in AML preclinical models. We hypothesized that voruciclib in combination with venetoclax would induce responses in patients with AML with disease progression after venetoclax therapy. This dose-escalation study evaluated voruciclib administered on days 1 to 14 of 28-day cycles with venetoclax daily. The study enrolled 41 adult patients with AML after failure of previous standard therapies. Patients had a median of 2 (range, 1-7) previous lines of therapy, 19 patients (46%) had ≥3 previous lines of therapy, and 39 (95%) had previous venetoclax. No dose-limiting toxicities were reported in 7 dose levels evaluated. The most common adverse events were nausea (34%), febrile neutropenia (32%), diarrhea (22%), dyspnea (22%), hypokalemia (22%), and thrombocytopenia (22%). Antileukemic activity was observed in 10 (24%) patients, including 3 with complete marrow remission and 7 with stable disease lasting ≥3 months. We observed a rebound of circulating blasts during the 14 days of single-agent venetoclax dosing in 40% of evaluable patients. Mcl-1 protein expression and RNA polymerase II Ser-2 phosphorylation decreased on voruciclib. Overall, the combination of voruciclib with venetoclax was tolerable in patients with relapsed/refractory AML, had antileukemic activity, and showed on-target effects in heavily pretreated patients with disease progression after venetoclax. This trial was registered at www.ClinicalTrials.gov as #NCT03547115.

2025-02-25·Blood Advances

A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Article

作者: Bhatt, Vijaya Raj ; Al Malki, Monzr M. ; Dominguez, Edward C. ; Danilov, Alexey V. ; Diefenbach, Catherine S. ; Abedin, Sameem ; Ghalie, Richard G. ; Brander, Danielle M. ; Davids, Matthew S. ; Dinner, Shira N. ; Javidi-Sharifi, Nathalie ; Roleder, Carly ; Rajagopalan, Prabhu ; Collins, Mary C. ; Wiley, Sandra E. ; Alvarado-Valero, Yesid ; Begna, Kebede H. ; Cook, Rachel J. ; Egan, Daniel N.

Abstract:

The antiapoptotic protein, myeloid cell leukemia-1 (Mcl-1), contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models. This dose escalation study evaluated voruciclib in patients with previously treated hematologic malignancies. Initially, voruciclib was administered daily, continuously, on a 28-day cycle (group 1). After 2 patients with prior allogeneic stem cell transplantation had a dose-limiting toxicity (DLT) of interstitial pneumonitis at 100 mg, voruciclib administration was changed to days 1 to 14 of a 28-day cycle (group 2). Forty patients, 21 with AML and 19 with B-cell malignancies, were enrolled. Patients had a median of 3 prior lines of therapy (range, 1-8). Dose escalation in group 2 was stopped at 200 mg, a dose that achieved plasma concentrations sufficient for target inhibition, without DLTs observed. The most common adverse events were diarrhea (30%), nausea (25%), anemia (22%), fatigue (22%), constipation (17%), dizziness (15%), and dyspnea (15%). In AML, 1 patient achieved a morphologic leukemia-free state, and 2 had stable disease. Voruciclib treatment led to a decrease in MCL1 messenger RNA expression, downregulation of myelocytomatosis (MYC) and NF-κB transcriptional gene sets, and reduced phosphorylation of RNA polymerase 2. Voruciclib on intermittent dosing was well tolerated, with no DLTs, paving the way for evaluation of the combination of voruciclib with venetoclax for patients with previously treated AML. This trial was registered at www.clinicaltrials.gov as #NCT03547115.

2024-09-01·ChemistrySelect

Computational Analysis of Phase I Metabolism in Clinically Studied Flavoalkaloids: Molecular Docking, MMGBSA Binding Energy Calculations, and Molecular Dynamics Simulations

作者: Kailas V. Kallurkar ; Sandip B. Bharate ; Shikha Thakur ; Hemant R. Jadhav

Abstract:

Flavoalkaloids, a potent class of cyclin‐dependent kinase inhibitors, have undergone extensive clinical trials across various cancer types. Among them, flavopiridol, riviciclib, and voruciclib are the most advanced candidates. These molecules are lipophilic and possess functional groups conducive to both phase I and phase II metabolism in the liver. This study employs in‐silico methods to identify the potential cytochrome P450‐mediated sites of phase I metabolism (SOM) in these compounds. According to two web‐server‐based predictions, the N ‐methyl group was identified as the primary SOM in these compounds, showing the highest probability score for involvement of CYP3A4. Docking studies conducted using both Glide and the induced‐fit method further confirmed N ‐demethylation as a significant metabolic pathway predominantly catalyzed by CYP3A4. The distance between the N ‐methyl group of the docked ligands and the iron atom of the heme ranged from 3 to 7 Å, with flavopiridol's N ‐methyl group positioned closest to the heme iron at 3.16 Å. The 100 ns molecular dynamic simulations additionally validated the stability of the interaction between flavoalkaloids and the heme Fe. Similarly, the docking‐based SOM predictions matched the experimental SOM for other approved drugs. Thus, employing docking‐based SOM predictions holds potential for enhancing lead optimization efforts in future medicinal chemistry research.

项与 Voruciclib Hydrochloride 相关的新闻（医药）

2026-05-13

·AmBeed 信号通路干货分享

细胞周期的“一组复合物，两类蛋白，三重检查点，四个阶段”是什么？一文速览

导语： “一组复合物，两类蛋白，三重检查点，四个阶段”——这短短十八个字，勾勒出细胞分裂的核心逻辑。从G1、S、G2到M期的四段旅程，由CDK(细胞周期依赖性激酶)与Cyclin(细胞周期蛋白)这对核心搭档形成不同的Cyclin-CDK复合物精密驱动，在G1/S、G2/M和SAC三大检查点的层层把关下，生命得以有序延续。然而，这套精密的调控系统一旦失控，癌症便悄然滋生。过去二十年，CDK4/6抑制剂的临床成功开启了靶向细胞周期的抗癌新纪元；而今，PROTAC、分子胶等技术正将这一领域推向新的高度。本文AmBeed将系统梳理细胞周期调控的基础机制、药物研发现状与前沿热点，助您快速掌握核心进展。 Section.01 Cyclin,CDK与Cyclin-CDK复合物 1.1 细胞周期蛋白Cyclin Cyclin是一类能够周期性地表达和降解的蛋白质，整个“周期蛋白超家族”则有近 29 个成员。人类“核心”细胞周期蛋白家族主要包括约 10 个成员，如Cyclin A、Cyclin B、Cyclin D和Cyclin E等。每个蛋白质的表达水平在细胞周期的不同阶段发生变化，并与特定的CDK形成复合物，从而调控细胞周期的进程[1, 5]。表1. Cyclin超家族成员及主要功能 1.2 细胞周期依赖性激酶CDK CDK是一类细胞周期依赖性激酶，人类基因组共编码20种CDKs，可分为三个功能亚家族：细胞周期CDK(CDK1、2、4、6)、转录CDK(CDK7、8、9、11、12、13)以及非典型CDK(CDK5、14~20)。细胞周期CDK—核心驱动力，必须与cyclin结合才能激活；转录CDK—调控RNA聚合酶II的活性，控制基因转录全过程；非典型CDK—在神经系统发育、代谢调控中发挥独特功能[1,2]。图1. CDK超家族及主要分类 CDK的活性受到四层精密调控：感知外界信号(如生长因子激活RAS-RAF-MEK-ERK通路)[1]；与Cyclin的结合周期波；CAK复合物(CDK7-Cyclin H-MAT1)的激活磷酸化与WEE1/MYT1的抑制性磷酸化；以及INK4家族和Cip/Kip家族两类CDK抑制剂的负向调控[1,2]。 1.3 Cyclin-CDK复合物细胞周期CDK构成细胞周期的核心引擎，通过与细胞周期蛋白Cyclin配对形成Cyclin-CDK复合物实现精准调控[1,2] 表2. 细胞周期相关Cyclin-CDK复合物 Section.02 细胞周期的“三查四阶段” 2.1 细胞周期的四个阶段细胞周期分为四个阶段：G1→S→G2→M，G1期，细胞生长并准备DNA复制；S期，DNA完成复制；G2期，继续生长并检查DNA完整性；M期，细胞进行有丝分裂，染色体分离[1,2]。表3. 细胞周期的四个阶段 2.2 细胞周期的三个检查点细胞周期中设有三个关键检查点，确保遗传信息准确传递[1,2]： G1/S检查点（限制点）：位于G1晚期，决定是否启动DNA复制。核心调控分子为Rb-E2F通路和p53-p21。这是细胞最重要的决策节点，也是癌细胞最常见的突变靶点（如p53、Rb缺失），导致细胞持续分裂。 G2/M检查点：位于G2期，检查DNA复制完整性与损伤。依赖CDK1-cyclin B及WEE1/MYT1/CDC25/CHK1等分子。纺锤体检查点（SAC）：位于M期早中期，确保所有染色体正确附着于纺锤体。由MAD2、BUBR1、CDC20和APC/C把关。表4. 细胞周期检查点及关键调控因子 Section.03 细胞周期药物前沿进展 3.1 靶向抑制：从泛CDKi到精准打击 CDK4/6抑制剂是目前临床最成功的范例。帕博西尼(Palbociclib)、瑞博西尼(Ribociclib)、阿贝西利(Abemaciclib)等已获批用于HR+/HER2-晚期乳腺癌[2,4]。关键III期PALOMA-1试验显示，帕博西尼联合来曲唑将中位无进展生存期从10.2个月延长至20.2个月[2]。然而，约30%的患者在2年内出现耐药，常见机制包括RB1缺失、CCNE1扩增及PI3K/AKT通路激活[4,6]。 CDK2抑制剂被视为克服CDK4/6耐药的下一个前沿。INX-315是一款高选择性口服CDK2抑制剂，已获得FDA针对CCNE1扩增卵巢癌的快速通道认定，目前正在开展治疗CDK4/6抑制剂耐药ER+/HER2-乳腺癌及CCNE1扩增实体瘤的I/II期临床试验[6,7]。研究表明，p16INK4A与Cyclin E1的共表达可预测CDK2抑制剂的敏感性，为临床精准筛选获益人群提供了生物标志物[7]。 CDK7抑制剂兼具双功能——CDK7不仅是细胞周期CDK的激活者（CAK），也是转录CDK。其抑制剂可同时打击细胞周期驱动和转录成瘾[4]。Samuraciclib是全球首个口服CDK7抑制剂。2025年底SABCS大会公布了II期SUMIT-BC阳性试验结果[9]；SY-5609属高选择性非共价口服CDK7抑制剂（KD=0.059 nM），正在TNBC及实体瘤中开展I期试验（NCT04247126）[10]。 WEE1抑制剂（如Adavosertib）通过“撤除有丝分裂刹车”诱导有丝分裂灾难，已在铂耐药卵巢癌等癌种中显示早期活性，目前处于2/3期临床试验[11]。 3.2 转录CDK：从细胞周期到转录调控的拓展转录CDK（CDK7、8/19、9、12/13）在基因表达调控不同环节发挥作用： CDK7：CDK7抑制剂Samuraciclib通过阻断RNA Pol II CTD磷酸化抑制转录起始[9]； CDK9：作为P-TEFb复合物催化亚基，其抑制剂Voruciclib等可有效降低Mcl-1等短寿抗凋亡蛋白水平，在急性髓系白血病等血液肿瘤中显示出早期疗效[13]； CDK12/13：通过维持DNA损伤反应相关长基因的转录延伸调控同源重组（HR）通路。CDK12突变的肿瘤对PARP抑制剂高度敏感，构成合成致死策略[12,15]。 3.3 从抑制到降解：PROTAC与分子胶开辟新范式与单纯抑制激酶活性不同，靶向蛋白降解技术，如PROTAC和分子胶，通过招募E3泛素连接酶，将靶蛋白彻底降解，从而消除了激酶活性和骨架功能。这种方法能更彻底地阻断致癌信号，有望克服传统抑制剂的耐药突变，并能靶向传统药物难以触及的“不可成药”靶点[3] CDK PROTAC：目前正快速发展，例如CDK2 PROTAC NKT3964已在临床前模型中显示出强大的抗增殖活性，其I期临床试验已完成首组患者给药，初步人体数据印证了口服生物利用度和药效学活性 [14]。CDK4/6 PROTAC可在低纳摩尔浓度下显著降解CDK4/6蛋白，在HR+乳腺癌模型中显示优于传统CDK4/6i的疗效，为克服功能性RB1缺失或Cyclin D1过表达导致的耐药提供了新策略[4]。CDK7 PROTAC CXJ2080和CDK9 PROTAC Compound 29在血液肿瘤和TNBC模型中也显示出潜力[16] 分子胶（Molecular Glues）：基于CR8的Cyclin K分子胶可促进CDK12与DDB1的相互作用，选择性降解Cyclin K，间接抑制CDK12/13活性[3] 3.4 双靶联合：CDK4/6与CDK7协同策略最新研究表明，双靶向CDK4/6和CDK7可协同抑制E2F驱动的转录放大效应，显著减少耐药细胞的出现，同时增强肿瘤微环境中的抗肿瘤免疫应答[4] 该组合在TNBC和CDK4/6抑制剂耐药的HR+/HER2-模型中均表现出持久抗肿瘤效果且耐受性良好。免疫分析显示，联合治疗能显著增加CD8+ T细胞浸润并逆转T细胞排除表型，提升IFN、TNF等炎症通路表达，促进肿瘤抗原特异性CD8+ T细胞应答[4]该策略为乳腺癌，尤其是Rb/E2F通路完整的亚型，开辟了全新的治疗窗口。 3.5 合成致死与免疫调节：新兴研究方向合成致死：基因组规模CRISPR筛选发现BAP1缺失与CDK4/6抑制剂耐药之间存在合成致死效应。CDK12缺陷的肿瘤对PARP抑制剂高度敏感，构成了新型合成致死联合策略[12,15]。免疫调节：CDK4/6抑制剂诱导的细胞衰老可产生衰老相关分泌表型（SASP），形成促炎微环境，联合senolytic药物或免疫检查点抑制剂可形成“双重打击”治疗策略。 Section.04 结语从细胞周期基础机制的揭示，到CDK抑制剂的临床成功应用，细胞周期调控领域在过去四十年中取得了跨越式进展。2025-2026年期间，我们看到了更多令人振奋的突破：新一代CDK4抑制剂和CDK7抑制剂在特定适应症中获得FDA突破性疗法认定，CDK2降解剂被大型药企成功引进，合成致死策略在多癌种中不断验证。在精准医学的时代背景下，细胞周期靶向治疗正从“一刀切”走向“基于生物标志物的个性化方案”。基础研究与临床转化的深度融合，将为癌症患者带来更多更优的治疗选择。 📚 参考文献 [1] Signal Transduct Target Ther. 2025 Jan 13;10(1):11.[2] Nat Rev Mol Cell Biol. 2022 Jan;23(1):74-88.[3] NPJ Precis Oncol. 2025 Jun 28;9(1):204.[4] J Clin Invest. 2025 Aug 12;135(20):e188839.[5] Applied Sciences. 2021;11(5):2320.[6] ClinicalTrials.gov: NCT05735080.[7] News release. Incyclix Bio. April 30, 2025.[8] Nat Commun. 2023 Jul 24;14(1):4444.[9] Carrick Therapeutics. 2025 SABCS.[10] ClinicalTrials.gov: NCT04247126.[11] Gynecol Oncol. 2023 Jul;174:239-246.[12] Clin Cancer Res. 2024 Dec 2;30(23):5445-5458.[13] Blood Adv. 2025 Feb 25;9(4):820-832.[14] Clinical Trials Arena. 2025-03-11.[15] Int J Biol Sci. 2024 Aug 19;20(11):4513-4531.[16] Leukemia. 2026 May;40(5):925-933. AmBeed产品推荐 Cell Cycle Signaling Pathway 更多查询官网 Palbociclib Palbociclib是一种高度特异性的Cdk4和Cdk6抑制剂, IC50分别为11 nM和16 nM. A295334 CDK4/6Ribociclib Ribociclib(LEE01)作为CDK4/6抑制剂具有高度特异性, IC50值分别为10 nM和39 nM, 对Cyclin B/CDK1复合物的效力低于1000倍. A288696 CDK4/6Abemaciclib Abemaciclib 是一种选择性的 CDK4/6 抑制剂, 对 CDK4 和 CDK6 的 IC50 值分别为 2 nM 和 10 nM. Abemaciclib 具有抗肿瘤作用, 可用于 HR+/HER2- 乳腺癌和其他肿瘤的研究. A106236 CDK4/6INX-315 INX-315 是一种新型、强效且具有高度选择性的细胞周期蛋白依赖性激酶 2 (CDK2) 抑制剂. 它对 CDK2/cyclin E1 复合体具有极高的抑制活性(生化 IC50 为 1.2 nmol/L, 细胞内靶向结合 IC50 为 2.3 nmol/L), 且对同家族的 CDK1、CDK4、CDK6 和 CDK9 具有极高的选择性. A2672606 CDK2 RO3306 RO-3306是一种强效且选择性的 CDK1 抑制剂, 对 CDK1/cyclin B1 的 Ki 值为 35 nM, 选择性是 CDK2/cyclin E 和 CDK4/cyclin D 的 10 倍和 50 倍以上. A138869 CDK1Dinaciclib Dinaciclib是一种有效的选择性 CDK 抑制剂, IC50 值分别为 CDK2 1 nM, CDK5 1 nM, CDK1 3 nM 和 CDK9 4 nM, 用于癌症研究. A196584 CDK1BMS265246 BMS-265246是一种强效且选择性抑制CDK1/2的抑制剂, 对CDK1/cyclin B和CDK2/cyclin E的IC50值分别为6和9 nM. A107996 CDK1Adavosertib Adavosertib (AZD-1775; MK-1775) 具有强效的Wee1抑制作用, IC50为5.2 nM. A399066 WEE1 AT7519 AT7519是一种广谱 CDKs 抑制剂, 对 CDK2/CyclinA、CDK5/p35 和 CDK9/CyclinT 的 IC50 值分别为47 nM、13 nM 和<10 nM, 且对其他 CDK 家族成员有不同程度的抑制作用. A485554 Pan-CDKJNJ7706621 JNJ-7706621是一种广谱 CDK 抑制剂, 能够抑制 CDK1/2 的 IC50 分别为 9 nM 和 4 nM, 同时也能强效抑制 Aurora A/B. A262123 Pan-CDKSamuraciclib Samuraciclib (CT7001或ICEC0942) 是一种首创的 (first-in-class)、具有口服生物利用度、高效且高选择性的 ATP竞争性细胞周期蛋白依赖性激酶 7 (CDK7) 抑制剂, IC50为40 nM. A1158422 CDK7(E/Z)-THZ1 (E/Z)-THZ1是一种 Cdk7 抑制剂 (IC50 介于 3.2-15.6 nM), 选择性靶向经典激酶域之外的远端半胱氨酸残基, 对 Cdk12 的激酶活性抑制作用较高 (IC50 = 250 nM). A303658 CDK7 Voruciclib Voruciclib是一种特异性抑制周期蛋白依赖性激酶 4(CDK4)的蛋白激酶抑制剂, 具有潜在的抗肿瘤活性. A380003 CDK9(R)-CR8 (R)-CR8 是一种强效的细胞周期蛋白依赖性激酶 (CDK) 抑制剂(主要针对 CDK1/2/5/7/9). (R)-CR8 也是一种新型的"分子胶"降解剂, 它能够将 CDK12-Cyclin K 复合物招募到 CUL4-DDB1-DCAF15 E3 泛素连接酶上, 从而特异性地介导靶蛋白 Cyclin K 的泛素化及蛋白酶体途径降解. A899287 CDK12-Cyclin K 往期推荐不止于经典：解密cAMP信号，洞悉其在癌症中的多重调控与治疗新靶点一文掌握AMPK信号通路——结构、激活与亚细胞功能全景解码细胞衰老：从分子机制到前沿干预策略宫颈癌的“幕后黑手”：HPV是如何一步步“策反”我们身体的？【AmBeed解读】2025年诺贝尔生理学或医学奖：揭秘外周免疫耐受的调节性T细胞革命破译结直肠癌（CRC）的密码:一文读懂核心通路与治疗靶点 D-荧光素钾盐的应用解析

2025-11-17

·GlobeNewswire-Health Care

Lite Strategy Reports First Quarter Fiscal Year 2026 Results; Highlights Successful Launch of $100M Litecoin Treasury Strategy and Movement into Active Capital Market Operations

LITS Is the First and Only US Publicly Traded Company to Gain Institutional Exposure to LTC, Holding 929,548 LTC TokensSAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Lite Strategy, Inc. (NASDAQ: LITS) (“Lite Strategy” or “LITS”) today reported results for its first quarter ended September 30, 2025, and highlighted recent corporate events related to the Company’s digital asset treasury strategy as well as its pharmaceutical operations. “Our first quarter was incredibly successful for LITS. We launched our digital treasury strategy, positioning ourselves as the leading public holder of LTC, and updated our corporate profile to reinforce our new focus,” Board Member Charlie Lee said. “We recently celebrated Litecoin’s 14th anniversary and its unblemished track record of reliability and uptime. LITS provides investors the only US publicly traded company to gain institutional exposure to Litecoin, both for portfolio diversification and long-term value.” “Fiscal year 2026 will showcase the results of the transformative steps taken by Lite Strategy. Since the start of our strategic alternatives process in fiscal year 2025, we have prioritized maximizing the value of our assets for stockholders. Starting with the successful sale of our clinical asset, ME-344 (now known as WE-868), currently being developed for adults with obesity at Aardvark Therapeutics, and continuing through the close of our $100 million PIPE offering in July 2025 that kicked off our Litecoin digital asset treasury strategy in the first quarter of this fiscal year,” said Jay File, CEO, CFO. First Quarter Fiscal Year 2026 and Recent Highlights Raised $100 million in aggregate gross proceeds, commencing the Company’s long-term strategic plan with Litecoin as a digital asset treasury reserve asset.Officially became the first U.S.-listed public company to adopt Litecoin as a primary reserve asset with the acquisition of 929,548 Litecoin (LTC) tokens, implementing a new strategy built on a digital asset infrastructure and long-term capital innovation.Entered into a strategic partnership with GSR, a leading crypto investment firm, to guide LITS’ digital asset treasury strategy, ensuring robust governance, execution, and market expertise.Brought on world-class board members, Charlie Lee, creator of Litecoin, and Joshua Riezman, U.S. Chief Strategy Officer at GSR.Rebranded from MEI Pharma to Lite Strategy, including changing the Company’s corporate name and NASDAQ Stock Market ticker from MEIP to LITS, and unveiling a new corporate logo and website. The rebranding underscores the Company’s commitment to building a long-term corporate strategy around LTC as its primary reserve asset.In October announced a $25 million share repurchase program, advancing LITS from the initial phase of Litecoin accumulation to active capital market operations and allowing LITS to leverage our nearly 1 million LTC treasury - a key differential from passive investment structures like exchange-traded funds. “As we progress further into fiscal year 2026, we continue to evaluate our clinical assets including the commencement of pre-clinical studies with voruciclib in non-oncology disease indications for potential licensing to third parties, and pursuing licensing or sale opportunities with zandelisib,” said Jay File. “We will consider opportunities to deploy our recently announced $25 million stock buyback program until our discount to NAV is normalized. We look forward to executing on all our corporate objectives as we progress through fiscal year 2026.” As of September 30, 2025, the Company had $12.21 million in working capital with no outstanding debt. To learn more about Lite Strategy, visit the Company’s homepage at https://litestrategy.com. To learn more about Litecoin and its role in Lite Strategy’s treasury, visit our About Litecoin page at https://litestrategy.com/about-litecoin/. To learn more about the transaction with Aardvark, read our Form 8-K filing at https://investor.meipharma.com/sec-filings/sec-filing/8-k/0000950170-24-117406. For current holdings and related Company metrics, visit Lite Strategy’s dashboard at https://litestrategy.com/dashboard/. About Lite Strategy, Inc. (LITS) Lite Strategy, Inc. (NASDAQ: LITS) is the first U.S. publicly traded company to adopt Litecoin as its primary reserve asset. Formerly MEI Pharma, the Company has expanded its business model beyond its portfolio of drug candidates to focus on pioneering institutional-grade digital asset treasury strategies, in partnership with leading innovators across blockchain, finance, and technology. Forward-Looking Statements Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding our future actions, prospective products and activities, future performance or results. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, risk relating to being able to repurchase our shares in the market on attractive e terms or at all, maintaining our current listing on Nasdaq, our ability to retain and attract senior management and other key employees, fluctuations in the market price of LTC and any associated impairment charges that we may incur as a result of a decrease in the market price of LTC below the value at which LTC is carried on our balance sheet, changes in the accounting treatment relating to our LTC holdings, our ability to achieve profitable operations, government regulation of cryptocurrencies and online betting, changes in securities laws or regulations, customer acceptance of new products and services including our LTC treasury strategy, our ability to utilize our repurchase program, the demand for our products and our customers’ economic condition, the impact of competitive products and pricing, our proprietary rights, general economic conditions and other risk factors detailed in our annual report and other filings with the SEC. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. Contacts: Justin J. FileCEO, CFO 858-369-7199investor@litestrategy.comSource: Lite Strategy, Inc.

并购财报IPO

2024-11-28

·PRNewswire

Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Advances in immunotherapy have ushered in a new era of treatment for follicular lymphoma (FL), particularly for patients who have experienced relapse after conventional chemotherapy regimens. This paradigm shift is characterized by the emergence of innovative therapies like CAR T-cell therapy and bispecific antibodies, which have demonstrated remarkable efficacy in targeting and eradicating lymphoma cells. CAR T-cell therapy represents a groundbreaking approach where a patient's own T-cells are genetically engineered to recognize and attack cancer cells. This personalized treatment has shown significant promise, especially for individuals who have undergone extensive previous therapies. One notable example is Axicabtagene ciloleucel (Yescarta), a CAR T-cell therapy approved for use in patients with relapsed or refractory follicular lymphoma. Clinical trials have highlighted its ability to induce durable remissions, with some patients experiencing long-term remission even after multiple prior therapies. LAS VEGAS, Nov. 28, 2024 /PRNewswire/ -- DelveInsight's ' Follicular Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline follicular lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the follicular lymphoma pipeline domain. Key Takeaways from the Follicular Lymphoma Pipeline Report DelveInsight's follicular lymphoma pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for follicular lymphoma treatment. Key follicular lymphoma companies such as Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others are evaluating new follicular lymphoma drugs to improve the treatment landscape. Promising follicular lymphoma pipeline therapies such as Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others are under different phases of follicular lymphoma clinical trials. In August 2024, the company expects to file a supplemental Biologics License Application for tafasitamab for the treatment of patients with FL who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy by the end of 2024 based on the positive Phase III results. In June 2024, a consortium of Eugene Private Equity and Korea Development Bank Private Equity announced that they would acquire 80% of South Korean vaccine maker Boryung Biopharma Co. for 320 billion won (USD 231 million). In February 2024, Incyte announced that it had entered into an asset purchase agreement with MorphoSys AG, which gives Incyte exclusive global rights for tafasitamab. Incyte will now recognize revenue and cost for all US commercialization and clinical development and MorphoSys will no longer be eligible to receive future milestone, profit split and royalty payments. In September 2023, OncoNano Medicine, Inc. announced a clinical trial supply agreement with Regeneron for the use of Libtayo (cemiplimab), a PD-1 inhibitor, in the combination stage of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate. The ONM-501 first-in-human trial is a multicenter Phase Ia/b dose escalation and dose expansion study of intratumoral ONM-501 as monotherapy and in combination with Libtayo in patients with advanced solid tumors and lymphomas. OncoNano is the sponsor of the clinical trial, and Regeneron will supply cemiplimab. In May 2023, Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies. Under the terms of the agreement, CBMG will grant Janssen a worldwide license to develop and commercialize the CAR-T assets, except in Greater China. Janssen and CBMG will negotiate an option for Janssen to commercialize the products in the Chinese territory. Janssen will make an upfront payment of USD 245 million that will be accounted for in the second quarter as a research and development expense. Additional future payments will be based upon achieving certain development, regulatory, and sales milestones, as well as tiered royalty payments on worldwide net trade sales, excluding Greater China. Request a sample and discover the recent advances in follicular lymphoma treatment drugs @ Follicular Lymphoma Pipeline Report The follicular lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage follicular lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the follicular lymphoma clinical trial landscape. Follicular Lymphoma Overview Follicular lymphoma is a common type of non-Hodgkin lymphoma (NHL) that originates from B-cells, a kind of white blood cell responsible for producing antibodies. This cancer is characterized by the growth of abnormal lymphoid follicles, which can disrupt normal lymphatic function. While the exact causes of follicular lymphoma are not fully understood, certain factors may increase the risk, including age (most commonly affecting adults over 60), a family history of lymphoma, and potential environmental factors such as exposure to pesticides or chemicals. Symptoms of follicular lymphoma can vary widely but may include painless swelling of lymph nodes in the neck, armpit, or groin, unexplained weight loss, night sweats, fatigue, and fever. Some patients may remain asymptomatic for extended periods, as this type of lymphoma can progress slowly. Diagnosis typically involves a combination of physical examinations, blood tests, imaging studies (like CT scans), and a biopsy of affected lymph nodes. The biopsy helps determine the subtype and stage of the lymphoma, which is crucial for planning treatment. Treatment for follicular lymphoma depends on the stage of the disease and the patient's overall health. Options may include watchful waiting for asymptomatic cases, chemotherapy, immunotherapy (such as monoclonal antibodies), and targeted therapies. In some cases, stem cell transplants may be considered for patients with more aggressive forms or those who do not respond to initial treatments. Given the indolent nature of follicular lymphoma, ongoing management, and regular monitoring are vital for achieving the best possible outcomes. Find out more about follicular lymphoma treatment drugs @ Drugs for Follicular Lymphoma Treatment A snapshot of the Follicular Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging follicular lymphoma pipeline therapies @ Follicular Lymphoma Clinical Trials Follicular Lymphoma Therapeutics Assessment The follicular lymphoma pipeline report proffers an integral view of the follicular lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Follicular Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule Therapeutics Assessment By Mechanism of Action: Phosphatidylinositol 3 kinase delta inhibitors, Phosphatidylinositol 3 kinase gamma inhibitors, Emt protein-tyrosine kinase inhibitors, Interleukin 15 receptor agonists, Histone deacetylase inhibitors, Rad51 recombinase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Apoptosis stimulants, Cell cycle inhibitors, Tubulin inhibitors, Tubulin polymerisation inhibitors, Enhancer of zeste homolog 2 protein inhibitors, Antibody-dependent cell cytotoxicity, Programmed cell death 1 receptor antagonists, T lymphocyte stimulants, Alkylating agents, DNA cross-linking agents Key Follicular Lymphoma Companies: Chia Tai Tianqing Pharmaceutical Group, Incyte Corporation, Mabworks, Johnson & Johnson Innovative Medicine, Nektar Therapeutics, Xynomic Pharmaceuticals, Merck Sharp & Dohme, Jiangsu HengRui Medicine Co., Ltd., ADC Therapeutics, Bristol-Myers Squibb, Swedish Orphan Biovitrum, Zhejiang DTRM Biopharma, Immpact Bio, Galapagos, Immunitas Therapeutics, Enterome, CRISPR Therapeutics, CHO Pharma, Shanghai Blueray Biopharma, BeiGene, AstraZeneca, AVM Biotechnology, Mustang Bio, Merck, Pell Bio-Med Technology, Schrodinger Inc., Sana Biotechnology, Poseida Therapeutics, OncoNano Medicine, Inc., Nurix Therapeutics, Inc., NovalGen, Pfizer, Xencor, Wellington Zhaotai Therapies, MEI Pharma, Sutro Biopharma, Synthekine, Verismo Therapeutics, Vincerx Pharma, Novartis, Century Therapeutics, Newave Pharmaceuticals, Bio-Path Holdings, Affimed GmbH, Iksuda Therapeutics, Allogene Therapeutics, Adicet Bio, Carna Biosciences, Inc., BeiGene, Boryung Pharmaceutical, Accutar Biotechnology, Atara Biotherapeutics, AbbVie, InnoCare Pharma, NeoImmuneTech, and others. Key Follicular Lymphoma Pipeline Therapies: Parsaclisib, TQ-B3525, Tafasitamab, MIL62, Ibrutinib, AZD0486, NKTR-255, Abexinostat, Acalabrutinib, Zilovertamab vedotin, SHR2554, Nivolumab, Loncastuximab tesirine, Golcadomide, Emapalumab, DTRM-555, Capivasertib, IMPT 314, GLPG5101, IMT-009, EO2463, CTX112, CHO-H01, BR1733, BGB-16673, BGB-10188, AZD5492, AVM0703, MB106, MK-1026, PL001, SGR-1505, SC291, SC262, P-CD19CD20-ALLO1, ONM 501, NX-5948, NX 2127, NVG-111, Mevrometostat, Plamotamab, WZTL-002, Voruciclib, STRO001, SYNCAR-001 + STK-009, SynKIR-310, VIP-152, VAY736, CNTY-101, LP-168, BP1002, IOA-244, IKS 03, ALLO-501, ADI-001, AS-1763, BGB-21447, BR101801, AC676, ATA3219, ABBV-319, ABBV-101, ICP-B02, ICP-B05, C-CAR039, Efineptakin Alfa, and others. Dive deep into rich insights for new drugs for follicular lymphoma treatment, visit @ Follicular Lymphoma Drugs Table of Contents For further information on the follicular lymphoma pipeline therapeutics, reach out @ Follicular Lymphoma Treatment Drugs Related Reports Follicular Lymphoma Market Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key follicular lymphoma companies including Epizyme, Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, among others. Non-Hodgkin Lymphoma Market Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Non-Hodgkin lymphoma companies, including Roche, Pfizer, Amgen, Novartis, Teva Pharmaceuticals, Genentech, ACD Therapeutics, among others. Non-Hodgkin Lymphoma Pipeline Non-Hodgkin Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Non-Hodgkin lymphoma companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc, among others. Diffuse Large B-cell Lymphoma Market Diffuse Large B-cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DLBCL companies, including AbbVie, Genmab, Merck, Roche, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

免疫疗法引进/卖出临床3期疫苗细胞疗法

100 项与 Voruciclib Hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15157

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	临床1期	美国	Lite Strategy, Inc.	2018-05-31
慢性淋巴细胞白血病	临床1期	美国	Lite Strategy, Inc.	2018-05-31
弥漫性大B细胞淋巴瘤	临床1期	美国	Lite Strategy, Inc.	2018-05-31
滤泡性淋巴瘤	临床1期	美国	Lite Strategy, Inc.	2018-05-31
套细胞淋巴瘤	临床1期	美国	Lite Strategy, Inc.	2018-05-31
边缘区B细胞淋巴瘤	临床1期	美国	Lite Strategy, Inc.	2018-05-31
小淋巴细胞淋巴瘤	临床1期	美国	Lite Strategy, Inc.	2018-05-31
复发性慢性淋巴细胞白血病	临床1期	美国	Piramal Enterprises Ltd.	2014-06-01
不可切除的黑色素瘤	临床1期	美国	Piramal Enterprises Ltd.	2013-08-01
晚期癌症	临床1期	加拿大	Piramal Enterprises Ltd.	2008-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03547115 (phase 1 study of the CDK9 inhibitor voruciclib, Pubmed \| Blood Adv)	临床1期	慢性淋巴细胞白血病 \| 难治性急性髓细胞白血病 Mcl-1	-	Voruciclib	獵願夢襯齋範鑰齋鬱襯(顧獵窪選廠製淵壓夢襯) = 22% 遞廠襯壓範簾餘範選網 (蓋齋構鹹顧鑰繭壓繭築 ) 更多	积极	2025-02-25
NCT03547115 (ASH2024) 人工标引	临床1期	急性髓性白血病	41	VoruciclibVenetoclax	壓襯積廠壓製構餘簾壓(鑰鹽廠糧夢衊膚鏇餘築) = None 夢遞鹹餘築淵艱簾範鹽 (壓餘觸壓餘齋艱膚壓餘 ) 更多	积极	2024-12-08
NCT03547115 (ASH2023)	临床1期	急性髓性白血病 \| B细胞淋巴瘤	40	Voruciclib	艱壓鏇顧範餘夢衊衊遞(鹽鏇網觸窪簾鬱餘憲醖) = downregulation of MYC transcriptional program and oxidative phosphorylation in circulating AML blasts, both evident 24 hours after start of voruciclib and ongoing at C1D15 齋網壓鑰選鏇襯餘膚蓋 (醖顧糧網艱醖鑰憲網遞 ) 更多	-	2023-12-11
NCT01841463 (ASCO2015) 人工标引	临床1期	BRAF突变阳性黑色素瘤	9	P1446A-05+vemurafenib	獵顧襯鹹簾艱鬱廠壓範(窪廠選鏇製齋夢蓋鹽積) = None 夢醖鏇糧範鹹憲鹽鑰顧 (蓋淵窪觸餘齋廠餘鏇鏇 ) 更多	积极	2015-05-20
ASCO2012	临床1期	肿瘤	29	P1446A-05	襯餘築願觸餘夢鹹範艱(觸獵獵餘鏇築繭醖淵鏇) = 艱顧顧簾選壓觸範繭顧憲鑰獵窪窪簾淵積夢壓 (網鏇醖繭鏇簾鹽遞顧夢 ) 更多	-	2012-05-20
ASCO2012	临床1期	-	-	P1446A-05 350mg	繭網製築簾遞觸艱鹽簾(獵積選鹹齋網積膚窪淵) = 顧廠淵鹽膚衊艱網構網網夢製憲夢窪鹹膚夢範 (範遞糧窪遞蓋製鹹鹹積 )	-	2012-05-20